Rise in the number of individuals battling dermatophytic onychomycosis is responsible for the growth of dermatophytic onychomycosis treatment market.
The aging population is at a higher risk of developing fungal infections in the nails due to their immobility regarding personal hygiene. This section of the global population forms the major consumer base for dermatophytic onychomycosis treatment industry.
The companies operating in dermatophytic onychomycosis treatment market are focusing on incorporation of combination treatment in order to obtain noticeable outcomes of dermatophytic onychomycosis treatment.
They are also reaching out to the under-developed economies of Middle East & Africa and Latin America to broaden their end-consumer base.
Onychomycosis is referred to as the nail unit’s fungal infection. When this condition is caused by dermatophytes, the condition is termed as tinea unguium. Onychomycosis can cause infections of both, toenails and fingernails, but onuchomycosis of toenail is more prevalent.
Initially, in the U.S., trichopjyton rubrum was looked upon as a culture contaminant. However, post-international travel to Asia Pacific, T.rubrum has turned out to be one of the dominant causative organisms in the U.S. Patients are genetically susceptible to these infections in autosomal dominant pattern.
The risk factors include aging, tinea pedis, psoriasis, and staying with the family members suffering from onychomycosis.
Side-effects of antifungal drugs such as dizziness, headache, stomach ache, and nausea may restrain the dermatophytic onychomycosis treatment industry. Topical agents are also likely to cause itchiness and rash in the surrounding skin.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Prevalence of dermatophytic onychomycosis worldwide ranges between 2% and 50%. It represents nearly 30% of the superficial mycotic infections and half of all the nail disorders.
Usually it affects adults aged between 30 and 60, but extra care needs to be taken while administering drugs to the population aged above 60 to do away with the interference by other drugs. Research says that over 75% of aging population suffers from toenail fungus.
Majority of end-consumers do not bother to visit the doctor if toenail fungus does not bother them. However, if nail fungus turns out to be painful and has resulted in thickening of nails, OTC medications and self-care steps can help. The treatment, even though successful, is likely to come back.
Recurrence of dermatophytic onychomycosis is thus expanding the dermatophytic onychomycosis treatment market size.
Dermatophytic onychomycosis has a higher prevalence amongst the older population. The other risk factors comprise tinea pedis, diabetes, poor circulation, psoriasis, immunosuppression, obesity, and occlusive footwear.
Treating the geriatric population for any ailment can prove to be challenging due to higher rates of recurrence (owing to lower resistance power) and non-responsiveness to treatment. Moreover, treatments need a lengthy duration of treatment, which could pose risk of adverse effects and overlapping with the other drugs.
As per the WHO, 1 billion individuals were aged 60 and above in 2020 alone. Dermatophytic onychomycosis topical as well as oral treatment drugs are undergoing extensive research to suit this geriatric population in order to check that one medication does not turn out to be detrimental to the other ailment.
Customized research for geriatric population to treat dermatophytic onychomycosis is thus driving the dermatophytic onychomycosis treatment market demand.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest dermatophytic onychomycosis treatment market analysis, North America dominated the nail dystrophy treatment landscape in 2023 and the status quo is expected to remain unchanged during the forecast period.
This is attributed to growing number of prescriptions for treatment of onychomycosis in the U.S. For instance, according to press release by Moberg Pharma AB, the total number of yearly prescriptions written for this treatment in North America is close to 5 million.
Besides, in April 2020, Bausch Health Companies Inc. announced that the U.S. FDA had approved its supplemental novel drug application for JUBLIA (efinaconazole) topical solution.
Europe’s significant dermatophytic onychomycosis treatment market growth is ascribed to rise in preferences for generic drugs along with enhanced OTC drug distribution for dermatophytic pnuchomycosis treatment. As per the Journal of the European Academy of Dermatology and venereology, 4.3% of the European population suffers from dermatophytic onychomycosis.
The key players in dermatophytic onychomycosis treatment market are opting for inorganic as well as organic modes of expansion to establish a strong foothold in the antifungal nail treatment landscape.
For instance, in July 2021, Almirall S.A. inked a license and distribution agreement with Kaken Pharmaceutical to develop and commercialize topical antifungal efinaconazole in Europe. In April 2021, Aleor Dermaceuticals received tentative approval from the U.S. FDA for efinaconazole topical solution to treat fungal toenail infections.
Dermatophytic onychomycosis treatment market report highlights GSK plc, Bausch Health, Pfizer Inc., GALDERMA, Johnson & Johnson Health Care Systems Inc., Cipla Limited, KAKEN Pharmaceutical Co., Ltd. based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 4.9 Bn |
| Market Forecast (Value) in 2034 | US$ 11.2 Bn |
| Growth Rate (CAGR) | 7.8% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 4.9 Bn in 2023
It is projected to grow at a CAGR of 7.8% from 2024 to 2034
Growing prevalence of dermatophytic onychomycosis and increase in geriatric population
Hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
GSK plc, Bausch Health, Pfizer Inc., GALDERMA, Johnson & Johnson Health Care Systems Inc., Cipla Limited, KAKEN Pharmaceutical Co., Ltd., and Others
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Dermatophytic Onychomycosis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Dermatophytic Onychomycosis Treatment Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Dermatophytic Onychomycosis Treatment Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2020-2034
6.3.1. Tablets
6.3.1.1. Prescription
6.3.1.2. Over-the-Counter
6.3.2. Nail Paints
6.3.2.1. Prescription
6.3.2.2. Over-the-Counter
6.4. Market Attractiveness Analysis, by Product Type
7. Global Dermatophytic Onychomycosis Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2020-2034
7.3.1. Oral
7.3.2. Topical
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Dermatophytic Onychomycosis Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Dermatophytic Onychomycosis Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Dermatophytic Onychomycosis Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2020-2034
10.3.1. Tablets
10.3.1.1. Prescription
10.3.1.2. Over-the-Counter
10.3.2. Nail Paints
10.3.2.1. Prescription
10.3.2.2. Over-the-Counter
10.4. Market Value Forecast, by Route of Administration, 2020-2034
10.4.1. Oral
10.4.2. Topical
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Product Type
10.7.2. By Route of Administration
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Dermatophytic Onychomycosis Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2020-2034
11.3.1. Tablets
11.3.1.1. Prescription
11.3.1.2. Over-the-Counter
11.3.2. Nail Paints
11.3.2.1. Prescription
11.3.2.2. Over-the-Counter
11.4. Market Value Forecast, by Route of Administration, 2020-2034
11.4.1. Oral
11.4.2. Topical
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Dermatophytic Onychomycosis Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2020-2034
12.3.1. Tablets
12.3.1.1. Prescription
12.3.1.2. Over-the-Counter
12.3.2. Nail Paints
12.3.2.1. Prescription
12.3.2.2. Over-the-Counter
12.4. Market Value Forecast, by Route of Administration, 2020-2034
12.4.1. Oral
12.4.2. Topical
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Product Type
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Dermatophytic Onychomycosis Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2020-2034
13.3.1. Tablets
13.3.1.1. Prescription
13.3.1.2. Over-the-Counter
13.3.2. Nail Paints
13.3.2.1. Prescription
13.3.2.2. Over-the-Counter
13.4. Market Value Forecast, by Route of Administration, 2020-2034
13.4.1. Oral
13.4.2. Topical
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Product Type
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Dermatophytic Onychomycosis Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Product Type, 2020-2034
14.3.1. Tablets
14.3.1.1. Prescription
14.3.1.2. Over-the-Counter
14.3.2. Nail Paints
14.3.2.1. Prescription
14.3.2.2. Over-the-Counter
14.4. Market Value Forecast, by Route of Administration, 2020-2034
14.4.1. Oral
14.4.2. Topical
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Product Type
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. GSK plc
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Bausch Health
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Pfizer Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. GALDERMA
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Johnson & Johnson Health Care Systems Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Cipla Limited
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. KAKEN Pharmaceutical Co., Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Others
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
List of Tables
Table 01: Global Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 02: Global Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 03: Global Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 07: North America Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 08: North America Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 09: Europe Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 11: Europe Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 12: Europe Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 13: Asia Pacific Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 15: Asia Pacific Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 16: Asia Pacific Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 17: Latin America Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 19: Latin America Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 20: Latin America Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 21: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
Table 23: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 24: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Dermatophytic Onychomycosis Treatment Market Revenue (US$ Bn), by Product Type, 2023
Figure 03: Global Dermatophytic Onychomycosis Treatment Market Value Share, by Product Type, 2023
Figure 04: Global Dermatophytic Onychomycosis Treatment Market Revenue (US$ Bn), by Route of Administration, 2023
Figure 05: Global Dermatophytic Onychomycosis Treatment Market Value Share, by Route of Administration, 2023
Figure 06: Global Dermatophytic Onychomycosis Treatment Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 07: Global Dermatophytic Onychomycosis Treatment Market Value Share, by Distribution Channel, 2023
Figure 08: Global Dermatophytic Onychomycosis Treatment Market Value Share, by Region, 2023
Figure 09: Global Dermatophytic Onychomycosis Treatment Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 11: Global Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 13: Global Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 14: Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 15: Global Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 16: Global Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Dermatophytic Onychomycosis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 22: North America Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 23: North America Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 24: North America Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 26: North America Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 27: Europe Dermatophytic Onychomycosis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 31: Europe Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 32: Europe Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 33: Europe Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 35: Europe Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 36: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 40: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 41: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 42: Asia Pacific Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 44: Asia Pacific Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 45: Latin America Dermatophytic Onychomycosis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 49: Latin America Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 50: Latin America Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 51: Latin America Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 53: Latin America Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 54: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 58: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 59: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 60: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 62: Middle East & Africa Dermatophytic Onychomycosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Dermatophytic Onychomycosis Treatment Market
